Immuno-oncology imaging firm ImaginAb has started patient enrolment in a Phase II clinical trial of its CD8 tracer 89Zr-Df-IAB22M2C to visualise T-cells and enable personalised treatment.

The first patient has been enrolled at City of Hope, a research and treatment centre in Los Angeles County, California, US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

89Zr-Df-IAB22M2C is an imaging agent that uses non-invasive, whole-body in-vivo PET imaging of CD8 T cells to visualise the immune system.

The technology leverages ImaginAb’s Minibody platform to target and visualise CD8+ T-cells to offer specific and quantitative assessment of the immunological status of each cancer lesion in a patient.

This approach is expected to facilitate tailored treatment based on the needs of individual patients.

ImaginAb CEO Ian Wilson said: “ImaginAb’s goal is to provide target-specific imaging agents to predict, inform, monitor and enable treatment of cancer disease more effectively.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

City of Hope expands the ImaginAb active sites performing Phase II baseline / on-treatment trials to evaluate the use of 89Zr-Df-IAB22M2C.

During the trial, the PET tracer’s utility in imaging CD8 T cells before (baseline) and after (on-treatment) cancer patients undergo immunotherapy-based treatment will be investigated.

Metastatic cancer patients will be recruited into the trial, which will explore the link between imaging signals observed using ImaginAb’s ImmunoPET imaging agent, standard-of-care scans and also immunohistochemistry analysis of CD8 in biopsied tissues.

The study will also measure changes in CD8+ T-cell distribution prior to and after immuno-oncology therapies.

ImaginAb is developing a pipeline of in-vivo antibody-based imaging agents to drive the development of therapeutic antibodies, diagnose disease, and aid precision medicine.